

TABLE OF CONTENTS: SUPPLEMENTAL MATERIAL

Supplemental Table 1: Linear mixed model analysis of average daily corticosteroid dose (in 10 mg/m²) with fixed effects at three-levels, for first presentation patients

Supplemental Table 2: Linear mixed model analysis of duration of corticosteroid treatment (in days) with fixed effects at three-levels, for first presentation patients

Ethics Approval (Identification) Numbers from CHILDNEPH sites

The following tables are the results of the linear mixed models for patients who entered at first presentation only.

Variable (Fixed-effects Parameters)	coefficient	P-value	95% C. I
Age at enrollment, years	-0.07	<0.001	-0.09, -0.05
Sex (ref: Male)	0.06	0.508	-0.11, 0.22
Ethnicity (Caucasian)			
South Asian	-0.21	0.110	-0.46, 0.05
African	0.07	0.831	-0.54, 0.68
Indigenous	0.21	0.340	-0.22, 0.64
East Asian	-0.22	0.134	-0.51, 0.07
Others	-0.10	0.354	-0.31, 0.11
Physician sex (ref: Male)	0.03	0.711	-0.15, 0.22
Physician practice years	**	0.998	-0.01, 0.01
Physician university (ref: Canadian)			
Non-Canadian	0.06	0.628	-0.18, 0.30
Both	-0.40	0.338	-1.22, 0.42
Site protocol (ref: no standard protocol)	0.25	0.460	-0.41, 0.91
Variable (Random-effects Parameters)	Estimate (SD)	SE	95% CI
Site	0.47	0.14	0.27, 0.83
Physician	**	0.01	**
Patient	0.36	0.05	0.27, 0.47
Residual	0.84	0.02	0.80, 0.89

Supplemental Table 1: Linear mixed model analysis of average daily corticosteroid dose (in 10 mg/m²) with fixed effects at three-levels, for first presentation patients (n=273)

(*) means the p-value is <0.05, the result is statistically significant. SD: standard deviation; SE: standard error; CI: confidence interval. (**) close to zero estimate

Variable (Fixed-effects parameters)	coefficient	P-value	95% CI
Age at enrollment, years	0.29	0.698	-1.17, 1.76
Sex (ref: Male)	0.96	0.865	-10.08, 11.99
Ethnicity (Caucasian)			
South Asian	-4.50	0.603	-21.44, 12.44
African	-15.25	0.482	-57.77, 27.26
Indigenous	41.92	0.005	12.72, 71.11
East Asian	4.44	0.654	-14.97, 23.86
Others	4.96	0.471	-8.53, 18.46
Physician sex (ref: Male)	13.95	0.057	-0.42, 28.32
Physician practice years	-0.23	0.582	-1.03, 0.58
Physician university (ref: Canadian)			
Non-Canadian	5.34	0.546	-11.99, 22.68
Both	8.90	0.788	-56.11, 73.91
Site protocol (ref: no standard protocol)	0.24	0.986	-27.48, 27.96
Variable (Random-effects parameters)	Estimate (SD)	SE	95% CI
<i>Site</i>	18.12	5.84	9.63, 34.09
<i>Physician</i>	5.04	7.01	0.33, 76.95
<i>Patient</i>	5.81	14.49	0.04, 773.27
<i>Residual</i>	73.93	2.16	69.81, 78.30

Supplemental Table 2: Linear mixed model analysis of duration of corticosteroid treatment (in days) with fixed effects at three-levels, for first presentation patients (n =273)

(*) means the p-value is <0.05, the result is statistically significant. SD: standard deviation; SE: standard error; CI: confidence interval

Ethics Approval (Identification) Numbers from CHILDNEPH sites

SickKids Research Ethics Board REB 1000021384; University of Manitoba Bannatyne Campus Research Ethics Board (Health Research Ethics Board – HREB) HS16933 (H2013:420); University of Alberta Pro00037781; University of British Columbia Children’s and Women’s Health Research Ethics Board H13–03068; IWK Research Ethics Board 1016972; CHU Sainte-Justine L’approbation éthique 3950; McGill University Health Centre 13–84-PED; Children’s Hospital of Eastern Ontario Research Institute Research Ethics Board 14/188X; Western University Health Science Research Ethics Board 105459; and McMaster University Hamilton Integrated Research Ethics Board 15–384.